XML 26 R15.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Business segment information | 6 Months Ended
--- | ---
Jun. 30, 2018
Segment Reporting [Abstract] |
Business segment information | 9. Business segment information The table below present net sales, which includes product sales and marketing service fees, by reporting segment:
|  | Three Months Ended June 30, |
(U.S. Dollars, in thousands) |  | 2018 |  |  | 2017 |  |  | Change |
BioStim |  | $ | 48,211 |  |  | $ | 47,174 |  |  |  | 2.2 | %
Spine Fixation |  |  | 23,880 |  |  |  | 21,360 |  |  |  | 11.8 | %
Biologics |  |  | 14,668 |  |  |  | 15,661 |  |  |  | -6.3 | %
Extremity Fixation |  |  | 24,788 |  |  |  | 24,747 |  |  |  | 0.2 | %
Net sales |  | $ | 111,547 |  |  | $ | 108,942 |  |  |  | 2.4 | %
|  | Six Months Ended June 30, |
(U.S. Dollars, in thousands) |  | 2018 |  |  | 2017 |  |  | Change |
BioStim |  | $ | 94,374 |  |  | $ | 91,713 |  |  |  | 2.9 | %
Spine Fixation |  |  | 44,587 |  |  |  | 40,627 |  |  |  | 9.7 | %
Biologics |  |  | 29,003 |  |  |  | 30,648 |  |  |  | -5.4 | %
Extremity Fixation |  |  | 52,292 |  |  |  | 48,692 |  |  |  | 7.4 | %
Net sales |  | $ | 220,256 |  |  | $ | 211,680 |  |  |  | 4.1 | %
The primary metric used in managing the Company is non-GAAP net margin, which is an internal metric that the Company defines as gross profit less sales and marketing expense. The table below presents non-GAAP net margin by reporting segment:
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
(U.S. Dollars, in thousands) |  | 2018 |  |  | 2017 |  |  | 2018 |  |  | 2017 |
BioStim |  | $ | 21,298 |  |  | $ | 19,469 |  |  | $ | 40,244 |  |  | $ | 36,602 |
Spine Fixation |  |  | 2,887 |  |  |  | 2,696 |  |  |  | 4,148 |  |  |  | 4,703 |
Biologics |  |  | 6,247 |  |  |  | 6,470 |  |  |  | 12,327 |  |  |  | 12,641 |
Extremity Fixation |  |  | 7,002 |  |  |  | 6,766 |  |  |  | 15,160 |  |  |  | 13,178 |
Corporate |  |  | (251 | ) |  |  | (107 | ) |  |  | (402 | ) |  |  | (205 | )
Non-GAAP net margin |  | $ | 37,183 |  |  | $ | 35,294 |  |  | $ | 71,477 |  |  | $ | 66,919 |
General and administrative |  |  | 22,268 |  |  |  | 20,409 |  |  |  | 41,752 |  |  |  | 38,691 |
Research and development |  |  | 7,891 |  |  |  | 6,887 |  |  |  | 14,828 |  |  |  | 14,311 |
Operating income |  | $ | 7,024 |  |  | $ | 7,998 |  |  | $ | 14,897 |  |  | $ | 13,917 |
Interest income (expense), net |  |  | (251 | ) |  |  | 76 |  |  |  | (434 | ) |  |  | 121 |
Other income (expense), net |  |  | (4,752 | ) |  |  | 585 |  |  |  | (1,840 | ) |  |  | (3,763 | )
Income before income taxes |  | $ | 2,021 |  |  | $ | 8,659 |  |  | $ | 12,623 |  |  | $ | 10,275 |
Geographical information The table below present net sales by geographic destination for each reporting unit and for the consolidated Company:
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
(U.S. Dollars, in thousands) |  | 2018 |  |  | 2017 |  |  | 2018 |  |  | 2017 |
BioStim |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | $ | 48,202 |  |  | $ | 47,162 |  |  | $ | 94,339 |  |  | $ | 91,701 |
International |  |  | 9 |  |  |  | 12 |  |  |  | 35 |  |  |  | 12 |
Total BioStim |  |  | 48,211 |  |  |  | 47,174 |  |  |  | 94,374 |  |  |  | 91,713 |
Spine Fixation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 18,853 |  |  |  | 18,050 |  |  |  | 36,432 |  |  |  | 34,085 |
International |  |  | 5,027 |  |  |  | 3,310 |  |  |  | 8,155 |  |  |  | 6,542 |
Total Spine Fixation |  |  | 23,880 |  |  |  | 21,360 |  |  |  | 44,587 |  |  |  | 40,627 |
Biologics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 14,667 |  |  |  | 15,651 |  |  |  | 28,989 |  |  |  | 30,614 |
International |  |  | 1 |  |  |  | 10 |  |  |  | 14 |  |  |  | 34 |
Total Biologics |  |  | 14,668 |  |  |  | 15,661 |  |  |  | 29,003 |  |  |  | 30,648 |
Extremity Fixation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 7,023 |  |  |  | 6,741 |  |  |  | 13,939 |  |  |  | 13,320 |
International |  |  | 17,765 |  |  |  | 18,006 |  |  |  | 38,353 |  |  |  | 35,372 |
Total Extremity Fixation |  |  | 24,788 |  |  |  | 24,747 |  |  |  | 52,292 |  |  |  | 48,692 |
Consolidated |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 88,745 |  |  |  | 87,604 |  |  |  | 173,699 |  |  |  | 169,720 |
International |  |  | 22,802 |  |  |  | 21,338 |  |  |  | 46,557 |  |  |  | 41,960 |
Net sales |  | $ | 111,547 |  |  | $ | 108,942 |  |  | $ | 220,256 |  |  | $ | 211,680 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration